Tagged with ART

Talent A new report by Novartis looks at how leading talent in the technology industry is increasingly looking to bring their skillsets into the healthcare and life sciences industries against the backdrop of the fight against COVID-19.   Top tech talent sees a myriad of opportunities to leverage its knowledge in…

Belgium Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from it, the importance of Belgium to the European group, and the challenges of launching gene therapy Zolgensma® in Belgium.  …

Korea Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big Pharma in their oncology projects, and the potential to become a pan-Asian venture in the future.   It is very…

USA Dr Brett Monia, co-founder and CEO of RNA therapeutics pioneer Ionis Pharmaceuticals, outlines the company’s extremely promising development pipeline, commercial partnerships with Big Pharma, and his ambitious strategy to launch ten or more products by 2025.   We have many programs currently in Phase III development. All these medicines are…

Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19.   Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…

Rankings The top 10 of Pharmaceutical Exec’s Top 50 Companies 2020. Roche overtakes Pfizer to take the number one spot, followed by Novartis which moves up from third to second on the list. For the full list and extensive analysis, see the Pharma Exec website here.   Made with Visme Infographic Maker

China Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what makes its technology platform unique, and the challenges of attaining funding for cutting-edge innovation.   Despite being a relatively new company, in 2019, we raised the most money…

France David Lescuyer, managing director of fully integrated French CDMO Skyepharma, outlines how the COVID-19 crisis could usher in a new era for the pharmaceutical industry, with a renewed pan-industry understanding of the importance of robust global supply chains.   In order to increase the robustness of the global supply chain,…

Hong Kong Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong.   Our research within AI…

Mexico A compilation of the top 10 pharmaceutical companies in the Mexican pharmaceutical market based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA, Sanfer, Senosiain and Siegfried Rhein.   1. Sanofi Global CEO: Paul Hudson Country Chair: Fernando Sampaio Sanofi has had a…

USA Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global experiences in innovative biopharma and biosimilars are informing her leadership strategy in the US generics space. Lynch also outlines how greater uptake of biosimilar medicines can be fostered…

China Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on the Hong Kong Stock Exchange and their first product, toripalimab, being the first anti-PD-1 monoclonal antibody self-developed by a Chinese…